Thera-SAbDab

BRENTUXIMAB

>   Structural Summary
TherapeuticBrentuximab
TargetTNFRSF8
Heavy ChainQIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA
Light ChainDIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb ADC
IsotypeG1
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedBristol-Myers Squibb%3BCelgene Corporation%3BDana-Farber Cancer Institute%3BFondazione Italiana Linfomi%3BFox Chase Cancer Center%3BImmune Tolerance Network%3BLymphoma Academic Research Organisation%3BMassachusetts General Hospital%3BNational Cancer Institute %28USA%29%3BNational Institute of Allergy and Infectious Diseases%3BSeattle Genetics%3BStanford University%3BTakeda%3BTakeda Oncology%3BUNC Lineberger Comprehensive Cancer Center%3BWashington University School of Medicine
Conditions ApprovedAnaplastic large cell lymphoma%3BCutaneous T-cell lymphoma%3BHodgkin%27s disease%3BMycosis fungoides%3BT-cell lymphoma
Conditions ActiveAdult T-cell leukaemia-lymphoma%3BDiffuse large B cell lymphoma%3BGerm cell and embryonal neoplasms%3BMastocytosis%3BMesothelioma%3BNon-Hodgkin%27s lymphoma%3BPeripheral T-cell lymphoma%3BSezary syndrome%3BDiffuse scleroderma
Conditions DiscontinuedGraft-versus-host disease%3BLeukaemia%3BMultiple myeloma%3BSolid tumours%3BSystemic lupus erythematosus
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy